返回 
加入收藏
劳拉替尼一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的药物经济学评价
x
请在关注微信后，向客服人员索取文件
| 篇名： | 劳拉替尼一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的药物经济学评价 |
| TITLE： | Pharmacoeconomic evaluation of loratinib in the first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer |
| 摘要： | 目的 从中国卫生体系角度出发，评价劳拉替尼对比克唑替尼一线治疗间变性淋巴瘤激酶（ALK）阳性晚期非小细胞肺癌的经济性，为该药在我国除香港以外其他地区的产品定价及相关医疗决策提供参考。方法基于CROWN试验数据同时构建Markov模型和分区生存模型（模拟时限为10年，循环周期为4周），以质量调整生命年（QALY）作为效果指标计算增量成本-效果比（ICER），并通过单因素敏感性分析、概率敏感性分析、情景分析验证基础分析结果的稳健性。结果基于Markov模型的基础分析结果显示，相较于克唑替尼组，劳拉替尼组人均成本增加了17867588.63元，人均效用增加了1.76QALYs，ICER为10152038.99元/QALY；基于分区生存模型的基础分析结果显示，相较于克唑替尼组，劳拉替尼组人均成本增加了18009592.54元，人均效用增加了1.74QALYs，ICER为10350340.54元/QALY。2种模型单因素敏感性分析结果显示，无进展生存状态效用值、疾病进展状态效用值及劳拉替尼成本等参数对结果影响较大。概率敏感性分析结果显示，以1～3倍2020年中国人均国内生产总值作为意愿支付阈值时，劳拉替尼具有经济性的概率为0。建议劳拉替尼每100mg的单价为657.10～815.60元。结论对于一线治疗ALK阳性晚期非小细胞肺癌患者，劳拉替尼相对于克唑替尼的疗效更好，但以当前药价而言在我国并不具有经济性；合理降低药价可增加其具有经济性的概率。 |
| ABSTRACT： | OBJECTIVE To eva luate the economy of loratinib versus crizo tinib in the first-line treatment of anaplastic lymphoma kinase （ALK）-positive advanced non-small cell lung cancer （NSCLC）from the perspective of China ’s health system ， and to provide reference for the product pricing and related medical decisions of the drug in other regions of China except for Hong Kong. METHODS Markov model and partition survival model both constructed based on the CROWN data （the simulation time limit was 10 years and the cycle period was 4 weeks）；the quality adjusted life year （QALY）was used as the outcome index to calculate the incremental cost-effectiveness ratio （ICER）. One-way sensitivity analysis ，probability sensitivity analysis and scenario analysis were used to verify the robustness of the results. RESULTS The basic analysis results based on Markov model showed that compared with crizotinib group ，the per capita cost of loratinib group increased by 17 867 588.63 yuan，the per capita utility increased by 1.76 QALYs，and the ICER was 10 152 038.99 yuan/QALY. The basic analysis results based on the partition survival model showed that compared with the crizotinib group ，the Δ 基金项目：江苏省博士后科研资助计划项目（No.2021K496C）； per capita cost of loratinib group increased by 18 009 592.54 2020年度高校哲学社会科学研究一般项目（No.2020SJA0070） yuan，the per capita utility increased by 1.74 QALYs，and the ＊硕士研究生 。研究方向 ：药物经济学 、卫生经济与政策 。 E-mail：sunlei_cpu@163.com ICER was 10 350 340.54 yuan/QALY. The results of one-way # 通信作者：教授，博士生导师。研究方向：药物经济学、卫生经 sensitivity analysis of the two models both showed that 济与政策。E-mail：ma86128@sina.com progression-free survival （PFS）state utility v alue，progression- ·1102· China Pharmacy 2022Vol. 33 No. 9 中国药房 2022年第33卷第9期 disease（PD）state utility value and loratinib cost had great influence on the results. The results of probability sensitivity analysis showed that when 1-3 times of China ’s per capita GDP in 2020 was taken as the willingness to pay threshold ，the probability of loratinib being economical was 0. The recommended unit price of loratinib per 100 mg was 657.10-815.60 yuan. CONCLUSIONS For patients with ALK-positive advanced NSCLC ，loratinib is more effective than crizotinib in the first-line treatment ，but it is not economical under the current price ；reasonably lowering the price of loratinib can increase the probability of its economy. |
| 期刊： | 2022年第33卷第09期 |
| 作者： | 孙蕾，陈平钰，马爱霞 |
| AUTHORS： | SUN Lei，CHEN Pingyu ，MA Aixia |
| 关键字： | 劳拉替尼；克唑替尼；间变性淋巴瘤激酶；非小细胞肺癌；药物经济学评价 |
| KEYWORDS： | loratinib；crizotinib；anaplastic lymphoma kinase ；non-small cell lung cancer ；pharmacoeconomic evaluation |
| 阅读数： | 252 次 |
| 本月下载数： | 9 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
